Specific binding assay with an enzyme modulator as a labeling substance

• US 4,134,792 A
• Filed: 12/06/1976
• Issued: 01/16/1979
• Est. Priority Date: 12/06/1976
• Status: Expired due to Term

• Current Assignee: Miles Laboratories, Inc. (Bayer AG)
• Original Assignee: Miles Laboratories, Inc. (Bayer AG)
• Inventors: Christner, James E., Carrico, Robert J., Boguslaski, Robert C.
• Primary Examiner(s): Tanenholtz, Alvin E.
• Assistant Examiner(s): Fan, C. A.
• Application Number:
  US05/748,005
• Time in Patent Office: 771 Days
• Field of Search: 195/103.5 A, 195/99, 424/12
• US Class Current: 435/4
• CPC Class Codes: G01N 2470/04 Sandwich assay format
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10S 436/817 Steroids or hormones

Abstract

A specific binding assay method employing, as a labeling substance, a reversibly binding enzyme modulator for the detection of a ligand in a liquid medium. The method follows conventional specific binding assay techniques of either the homogeneous or heterogeneous type wherein the liquid medium to be assayed is combined with reagent means that includes a labeled conjugate to form a binding reaction system having a bound-species and a free-species of the conjugate. The amount of conjugate resulting in the bound-species or the free-species is a function of the amount of ligand present in the liquid medium assayed. In the present invention, the labeled conjugate comprises a reversibly binding enzyme modulator covalently linked to a binding component of the binding reaction system. The distribution of the conjugate between the bound-species and the free-species is determined by addition of an enzyme whose activity is affected, either decreased or increased, by said modulator and measuring the resulting activity of the enzyme. The enzyme modulator may be a conventional enzyme inhibitor, preferably of the coompetitive type, or an allosteric effector.

Claims

1. In a specific binding assay method for determining a ligand in a liquid medium,

wherein said liquid medium is combined with reagent means including a conjugate of a labeling substance and a binding component to form a binding reaction system having a bound-species and a free-species of said conjugate;

and

wherein the amount of ligand present in said liquid medium is determined as a function of the amount of labeling substance present in said bound-species or said free-species;

the improvement which comprises employing as said labeling substance a reversibly binding enzyme inhibitor, the binding constant for association of said inhibitor and an enzyme whose activity is inhibited thereby being less than about 10¹¹ molar^-1 ;

adding said enzyme whose activity is affected by said enzyme inhibitor to said bound-species or said free-species; and

determining the amount of said enzyme inhibitor therein by measuring the resulting activity of said enzyme.

2. A method as claimed in claim 1 wherein the binding constant for the association of said reversibly binding enzyme inhibitor and said enzyme is between about 10⁵ and about 10⁹ molar^-1.

3. A method as claimed in claim 1 wherein said reversibly binding enzyme inhibitor is a competitive inhibitor of the enzyme.

4. A method as claimed in claim 3 wherein said reversibly binding competitive inhibitor and the enzyme inhibited thereby are, respectively,

(a) acetazolamide, or an effective analog thereof, and carbonic anhydrase;

(b) sulfanilamide, or an effective analog thereof, and carbonic anhydrase;

(c) phenyl trimethylammonium ion, or an effective analog thereof, and acetylcholinesterase;

(d) saccharo-1,4-lactone, or an effective analog thereof, and β

-glucuronidase;

(e) 4-amino-10-methyl-pteroylglutamic acid, or an effective analog thereof, and dihydrofolate reductase;

or

(f) 2,6,8-trichloropurine, or an effective analog thereof, and uricase.

5. A method as claimed in claim 1 wherein said enzyme inhibitor, as a component of said conjugate, affects the activity of said enzyme differently when said conjugate is in said bound-species than when in said free-species.

6. A method as claimed in claim 5 of the homogeneous type wherein said enzyme is added to the combined bound-species and free-species.

7. A method as claimed in claim 1 of the heterogenous type wherein said bound-species and said free-species are physically separated, and said enzyme is added to one thereof.

8. A method as claimed in claim 1 wherein said ligand is selected from the group consisting of antigens and antibodies thereto;

haptens and antibodies thereto; and

hormones, vitamins, metabolites, and pharmacological agents, and their receptors and binding substances.

9. In a reagent means for use in determining a ligand in a liquid medium, which means includes a conjugate of a labeling substance and a binding component, which means and the ligand form a binding reaction system having a bound-species and a free-species of said conjugate,

the improvement wherein said labeling substance is a reversibly binding enzyme inhibitor and said means comprises additionally an enzyme whose activity is affected by said enzyme inhibitor, the binding constant for association of said inhibitor and said enzyme being less than about 10¹¹ molar^-1.

10. Means as claimed in claim 9 wherein the binding constant for the association of said reversibly binding enzyme inhibitor and said enzyme is between about 10⁵ and about 10⁹ molar^-1.

11. Means as claimed in claim 9 wherein said reversibly binding enzyme inhibitor is a competitive inhibitor of the enzyme.

12. Means as claimed in claim 11 wherein said reversibly binding competitive inhibitor and the enzyme inhibited thereby are, respectively,

(a) acetazolamide, or an effective analog thereof, and carbonic anhydrase;

(b) sulfanilamide, or an effective analog thereof, and carbonic anhydrase;

(c) phenyl trimethylammonium ion, or an effective analog thereof, and acetylcholinesterase;

(d) saccharo-1,4-lactone, or an effective analog thereof, and β

-glucuronidase;

(e) 4-amino-10-methyl-pteroylglutamic acid, or an effective analog thereof, and dihydrofolate reductase;

or

(f) 2,6,8-trichloropurine, or an effective analog thereof, and uricase.

13. Means as claimed in claim 9 wherein said enzyme inhibitor, as a component of said conjugate, affects the activity of said enzyme differently when said conjugate is in said bound-species than when in said free-species, said means comprising (i) said conjugate wherein said binding component is said ligand, a specific binding analog of said ligand, or a specific binding partner of said ligand, and (ii) if said binding component is said ligand or a specific binding analog thereof, a specific binding partner of said ligand.

14. Means as in claim 9 which comprises (i) said conjugate wherein said binding component is said ligand or a specific binding analog of said ligand, and (ii) a specific binding partner of said ligand.

15. Means as in claim 14 wherein one of said conjugate and said specific binding partner is in a form which is insoluble in said liquid medium.

16. Means as in claim 9 which comprises (i) said conjugate in a form which is soluble in said liquid medium and wherein said binding component is a specific binding partner of said ligand, and (ii) said ligand or a specific binding analog thereof in a form which is insoluble in said liquid medium.

17. Means as in claim 9 which comprises (i) said conjugate wherein said binding component is a specific binding partner of said ligand, and (ii) a specific binding partner of said ligand.

18. Means as in claim 17 wherein one of said conjugate and said specific binding partner is in a form which is insoluble in said liquid medium.

19. Means as in claim 9 wherein said ligand is selected from the group consisting of antigens and antibodies thereto;

haptens and antibodies thereto; and

hormones, vitamins, metabolites, and pharmacological agents, and their receptors and binding substances.